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Pharmacological LRRK2 kinase 
inhibition induces LRRK2 protein 
destabilization and proteasomal 
degradation
E. Lobbestael1, L. Civiero2, T. De Wit1, J.-M. Taymans3, E. Greggio2 & V. Baekelandt1
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, 
including the most common mutation, G2019S, and is known to play a role in Parkinson’s disease 
(PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors 
as one of the most prevailing disease-modifying therapeutic PD strategies. Although several lines of 
evidence support beneficial effects of LRRK2 kinase inhibitors, many questions need to be answered 
before clinical applications can be envisaged. Using six different LRRK2 kinase inhibitors, we show that 
LRRK2 kinase inhibition induces LRRK2 dephosphorylation and can reduce LRRK2 protein levels of 
overexpressed wild type and G2019S, but not A2016T or K1906M, LRRK2 as well as endogenous LRRK2 
in mouse brain, lung and kidney. The inhibitor-induced reduction in LRRK2 levels could be reversed by 
proteasomal inhibition, but not by lysosomal inhibition, while mRNA levels remained unaffected. In 
addition, using LRRK2 S910A and S935A phosphorylation mutants, we show that dephosphorylation 
of these sites is not required for LRRK2 degradation. Increasing our insight in the molecular and cellular 
consequences of LRRK2 kinase inhibition will be crucial in the further development of LRRK2-based PD 
therapies.
Leucine-rich repeat kinase 2 (LRRK2) kinase inhibition is currently one of the prevailing disease-modifying 
therapeutic strategies for Parkinson’s disease (PD)1. LRRK2 is a very attractive target since pathogenic LRRK2 
mutations are a common cause of inherited forms of PD2,3 and genetic variations in the LRRK2 locus are asso-
ciated with an increased risk to develop sporadic PD4–7. The most common pathogenic mutation, G2019S, 
increases kinase activity8–10, which plays a crucial role in mutant LRRK2-induced toxicity11–13 and can be reversed 
by LRRK2 kinase inhibition10,12,14,15. This has stimulated academic and industrial efforts on the development of 
potent and selective LRRK2 kinase inhibitors16,17.
LRRK2 is phosphorylated at multiple serines including S910, S935, S955 and S97318–20. Although these sites 
are most likely phosphorylated by other kinases18,19,20–27, the LRRK2 kinase domain appears to play a regulatory 
role in this phosphorylation event since all LRRK2 kinase inhibitors also induce LRRK2 dephosphorylation at 
S93522,28–30. Therefore, LRRK2 dephosphorylation at S935 is widely used as a surrogate readout for LRRK2 kinase 
inhibition in a cellular context29,30–32.
Before clinical applications can be envisaged, more insight in the molecular and cellular consequences of 
LRRK2 kinase inhibition will be needed since there might be (side) effects we do not fully understand to date. 
We have previously shown that LRRK2 kinase inhibition induces PP1-mediated LRRK2 dephosphorylation33. 
Although not proven to be a pathogenic mechanism, the fact that PP1-mediated dephosphorylation is also 
observed in most pathogenic mutants19,22,33,34, calls for caution when considering LRRK2 kinase inhibitors in 
the clinic. In addition, LRRK2 kinase inhibition can induce LRRK2 ubiquitination35 and a reduction of protein 
levels35–38, which may explain the cellular changes in the lung of non-human primates36 or mice39 treated with 
LRRK2 kinase inhibitor, given the close resemblance with the lung phenotype observed in LRRK2 knock-out 
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animals36,37,40,41. One of the important outstanding questions is whether this reduction of LRRK2 protein level 
is purely an unwanted effect or whether this might (partially) account for the beneficial effects of LRRK2 kinase 
inhibition. LRRK2 ablation was shown to protect against α -synuclein- and LPS-induced toxicity42,43 and a recent 
study postulated that reduced LRRK2 protein levels, rather than kinase inhibition, explains the beneficial effects 
on LRRK2-induced toxicity38. Together, these findings underline the importance of understanding LRRK2 kinase 
inhibitor-induced dephosphorylation and destabilization as a crucial step in the development of LRRK2 kinase 
inhibition as a PD therapy.
Given the fast LRRK2 dephosphorylation after LRRK2 kinase inhibition29, most published reports use kinase 
inhibitor treatment for a short period of time (minutes to hours). Here, we aimed to assess the effects of sustained 
LRRK2 kinase inhibition (hours to days) on cellular LRRK2 phosphorylation and protein stability as well as their 
relationship using phosphorylation mutants. With a view on therapeutic applications, we examined inhibition 
effects in neuronal and non-neuronal cells using wild type (WT) and pathogenic LRRK2 and different LRRK2 
kinase inhibitors.
Results and Discussion
Pharmacological LRRK2 kinase inhibition reduces LRRK2 protein levels in overexpressing cells. 
To investigate the effects of pharmacological LRRK2 kinase inhibition on LRRK2, SH-SY5Y cells with stable lenti-
viral vector-mediated overexpression of LRRK2 were treated with six different LRRK2 kinase inhibitors: MLi-239, 
PF-0644747544, GSK2578215A45, LRRK2-IN146, HG 10-102-0128 and CZC-2514647 (for more information see1). 
As expected, treatment of cells induced a rapid dephosphorylation at S935. In addition, treatment with each of the 
inhibitors resulted in a gradual decrease in LRRK2 protein levels, starting from 8 h of treatment (Fig. 1a).
The observation that six different LRRK2 kinase inhibitors, each with different selectivity profiles, reduce 
LRRK2 protein levels, points to a LRRK2-specific effect. This was further corroborated by the lack of LRRK2 
dephosphorylation and protein reduction after treatment of the inhibitor insensitive mutant A2016T46,48–50 with 
LRRK2-IN1, CZC-25146 or HG 10-102-01 (Fig. 1b). Interestingly, a trend towards LRRK2 protein destabiliza-
tion was observed for the HG 10-102-01 compound, which is reported to show strongly reduced activity against 
LRRK2 A2016T51. In addition, also the kinase dead LRRK2 variant K1906M, which was reported to display 
reduced sensitivity to several LRRK2 kinase inhibitors24, did not display S935 dephosphorylation and destabili-
zation upon inhibitor treatment (Fig. 1c).
To examine whether the inhibitor-induced destabilization also holds true for the most common pathogenic 
mutation G2019S, we performed the same experiment in SH-SY5Y cells stably overexpressing LRRK2 G2019S. 
As for LRRK2 WT, LRRK2 S935 dephosphorylation was observed starting from the 2 h time point, while LRRK2 
levels were decreased from 8 h treatment on (Fig. 1d).
Our results show that LRRK2 kinase inhibition induces LRRK2 dephosphorylation at S935 prior to a reduc-
tion in LRRK2 levels. To examine whether dephosphorylation of the cellular LRRK2 phosphorylation sites S910 
and S935 is crucial for the reduction of LRRK2 levels, we treated SH-SY5Y cells with stable overexpression of 
the LRRK2 phosphorylation mutants S910A or S935A (Fig. 1e,f). Interestingly, inhibitor-induced destabilization 
also occurred in these mutants that cannot be further dephosphorylated at S910 and S935, which indicates that 
LRRK2 dephosphorylation at S910 and S935 is not required for the reduction of LRRK2 levels. This is in line with 
the findings of Zhao et al.35 showing increased ubiquitination of the double S910A/S935A mutant upon inhibitor 
treatment. Future studies will need to elucidate whether LRRK2 dephosphorylation at other (auto)phosphoryla-
tion sites induces the reduction in protein levels or whether other factors such as conformational changes induced 
by binding of the inhibitor or the LRRK2 kinase inhibition itself, regulate LRRK2 protein levels.
Reduced LRRK2 protein levels result from increased proteasomal protein degradation. Next, 
we set out to gain mechanistic insight in the LRRK2 kinase inhibitor-induced reduction of LRRK2 protein levels. 
SH-SY5Y cells, overexpressing LRRK2, were treated for different periods of time with CZC-25146 followed by 
total RNA isolation and QPCR analysis. In parallel, cells were treated with inhibitor for subsequent immunob-
lotting analysis to confirm LRRK2 dephosphorylation and protein level reduction. QPCR analysis revealed that, 
although LRRK2 protein levels were dramatically decreased, LRRK2 mRNA levels remained constant during 
the entire experiment (Fig. 2a), pointing to a regulation at the protein level rather than a transcriptional event. 
Since WT LRRK2 has been mainly reported to be degraded by the ubiquitin proteasome system52–55, we treated 
LRRK2 overexpressing cells with LRRK2 kinase inhibitor together with the proteasomal inhibitor, MG132. 
Although LRRK2 kinase inhibition still induced LRRK2 dephosphorylation, no decrease in LRRK2 protein levels 
was observed when proteasomal activity was blocked (Fig. 2b). Conversely, chloroquine-mediated lysosomal 
inhibition was not able to rescue the LRRK2 kinase inhibitor-induced LRRK2 protein destabilization (Fig. 2c). 
Together, these findings strongly suggest that the inhibitor-induced reduction of LRRK2 protein levels can be 
mainly explained by proteasome-mediated LRRK2 degradation. This is in line with a recent report showing 
increased LRRK2 ubiquitination and degradation after LRRK2 kinase inhibition35.
LRRK2 kinase inhibition reduces endogenous LRRK2 protein levels in vivo. To further investigate 
the in vivo relevance of our findings, we examined the effect of LRRK2 kinase inhibition on endogenous LRRK2 
in mouse. Mice were injected four times with 10 mg/kg of the highly potent and selective LRRK2 kinase inhibitor 
MLi-2 or with DMSO. A significant decrease in LRRK2 phosphorylation at S935 and total protein levels was 
observed in mouse brain (Fig. 3). Given the reported abnormalities in LRRK2 KO mice56–59 and in LRRK2 kinase 
inhibitor-treated animals39,56, we also analyzed LRRK2 levels in lung and kidney of mice injected with MLi-2. As 
in brain, a significant decrease in P-S935 as well as total LRRK2 protein levels was observed in lung and kidney 
(Fig. 3). A reduction of LRRK2 protein levels in lung and kidney of mice was also reported after in-diet dosing 
with MLi-2, but no effect on LRRK2 levels in mouse cortex could be observed39. Still, a reduction in striatal 
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Figure 1. LRRK2 kinase inhibition reduces LRRK2 protein levels. SH-SY5Y overexpressing 3flag-LRRK2 
WT (a) A2016T (b) K1906M (c) G2019S (d) S910A (e) or S935A (f) were treated according to different 
time schedules with LRRK2-IN1 (L2-IN1, 1 μ M), CZC-25146 (CZC, 200 nM), PF-06447475 (PF, 150 nM), 
GSK2578215A (GSK, 1 μ M), MLi-2 (10 nM) or HG 10-102-01 (HG, 1 μ M) or DMSO. Cell lysates were analyzed 
with immunoblotting using FlagM2 antibody for LRRK2 detection, anti-LRRK2 P-S935 and anti-α - or β 
-tubulin, anti-GAPDH or anti-vinculin for equal loading. Shown are representative blots. Graphs show the 
quantification of blots representing the ratio of phosphorylation at S935 over total LRRK2 signal or total LRRK2 
over housekeeping protein signal. Error bars indicate s.e.m. with N ≥ 3. Statistical significance was tested using a 
two-way ANOVA test with Bonferroni post-tests. ***p < 0.001, **p < 0.01, *p < 0.05.
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LRRK2 protein levels has been reported in non-human primates treated with GNE-087756. It will be interesting 
to further investigate whether this discrepancy can be explained by differences between brain regions, or rather 
to technical aspects such as buffer composition. Interestingly, in contrast to full length LRRK2, protein stability 
of the truncated form of LRRK2 in kidney (~170 kD) was not affected upon LRRK2 kinase inhibition, although 
S935 dephosphorylation was evident (Fig. 3). This is in line with the reported reduction in full length, but not the 
truncated, LRRK2 protein levels in the kidney of mice treated with a Novartis LRRK2 kinase inhibitor57.
LRRK2 kinase inhibition in primary astrocytes. To investigate the effect of LRRK2 kinase inhibition 
on endogenous LRRK2 in brain cells other than neurons, we used primary astrocyte cultures. Treatment of pri-
mary astrocytes with the kinase inhibitors GSK2578215A, CZC-25146, HG 10-102-01 or PF-06447475 for up to 
48 h did induce significant S935 dephosphorylation but not destabilization of endogenous LRRK2 (Fig. 4). Also 
sustained LRRK2 kinase inhibition for several days did not induce destabilization, except for the GSK2578215A 
(Fig. 4).
Figure 2. LRRK2 kinase inhibitor-induced reduction of LRRK2 protein levels is caused by proteasomal 
degradation. (a) QPCR analysis was performed on mRNA derived from SH-SY5Y cells overexpressing 3flag-
LRRK2 WT, treated with CZC-25146 (CZC, 200 nM) or DMSO for different periods of time. Immunoblotting 
analysis was performed on cells cultured and treated in parallel with cells for QPCR analysis, using FlagM2 
antibody for LRRK2 detection, anti-LRRK2 P-S935 and anti-β -tubulin for equal loading. Shown are 
representative blots. Quantification of LRRK2 mRNA shows LRRK2 mRNA levels normalized to β -actin 
mRNA levels with error bars indicating s.e.m., N = 3. (b) SH-SY5Y cells overexpressing 3flag-LRRK2 WT were 
treated for 17 h with LRRK2-IN1 (L2-IN1, 1 μ M) and/or MG132 (1 μ M), DMSO was used as negative control. 
Cell lysates were analyzed with immunoblotting using FlagM2 antibody for LRRK2 detection, anti-LRRK2 
P-S935 and anti-β -tubulin for equal loading, N ≥ 4. Statistical significance was assessed by column statistics 
(one-sample t-test) or a nonparametric t-test (Mann-Whitney). **p < 0.01; *p < 0.05. (c) SH-SY5Y cells 
overexpressing 3flag-LRRK2 WT were treated for 48 h with LRRK2-IN1 (L2-IN1, 1 μ M) and/or chloroquine 
(CQ) (10 μ M), DMSO was used as negative control. Cell lysates were analyzed with immunoblotting using 
FlagM2 antibody for LRRK2 detection, anti-LRRK2 P-S935, anti-LC3 antibody and anti-α tubulin for equal 
loading, N ≥ 4. Statistical significance was assessed by column statistics (one-sample t-test) with Bonferroni 
correction or a nonparametric t-test (Mann-Whitney). **p < 0.01; *p < 0.05.
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A more in-depth study in primary astrocytes is needed to explain why not all inhibitors where able to induce 
LRRK2 destabilization. In addition, it will be interesting to investigate the effects of kinase inhibition in other cell 
types such as microglial cells.
By using six compounds with different selectivity profiles, the A2016T mutant and different test systems we 
provide robust evidence that pharmacological LRRK2 kinase inhibition can induce proteasomal LRRK2 protein 
degradation in different cell types in a LRRK2 inhibitor-specific manner.
This is in line with previous studies reporting reduced LRRK2 protein levels after kinase inhibitor treatment of 
cells overexpressing LRRK235,38, and in kidney35–37 or lung35 of WT mice. Given the fast effects of LRRK2 kinase 
inhibition (LRRK2 dephosphorylation within 30 min29), most studies have not applied LRRK2 kinase inhibitor 
treatment for a time span longer than 2 h. This most likely explains why the ‘delayed’ degradation of LRRK2 (more 
than 2 h after inhibition) in cell lines overexpressing LRRK2 has not been observed in most reports. Interestingly, 
LRRK2 kinase inhibition in vivo does not induce destabilization in all conditions. PF-06447475 treatment in mice 
for 90 minutes44 and in rats for 14 days60 does not induce reduced LRRK2 levels in the brain, while we observed a 
significant reduction of LRRK2 protein levels upon PF-06447475 treatment of LRRK2 overexpressing cell lines. 
As mentioned before, in-diet MLi-2 treatment of mice caused LRRK2 protein destabilization in lung and kidney, 
but not in the cortex39, while we also observed clear destabilization in full brain extracts. Identification of the 
key variables in LRRK2 kinase inhibitor-induced LRRK2 protein destabilization will be crucial to explain the 
observed differences.
Inhibitor-induced LRRK2 protein degradation is an important ‘side’ effect, which needs to be considered in 
view of clinical applications. Future studies should therefore be directed at understanding how LRRK2 destabili-
zation is triggered and how it takes place. Understanding whether reduced LRRK2 levels are beneficial or rather 
an unwanted effect of LRRK2 kinase inhibition will be crucial to pursue or redirect current pharmacological 
LRRK2 therapeutic strategies.
Materials and Methods
Antibodies and reagents. LRRK2 kinase inhibitor-1 (L2-IN1), HG 10-102-01 and CZC-25146 were pur-
chased from Calbiochem, GSK2578215A from Tocris and PF-06447475, MG132 and chloroquine from Sigma-
Aldrich. MLi-2 was kindly provided by Dr. D. Alessi (Division of Signal Transduction Therapy, University of 
Figure 3. LRRK2 kinase inhibition in vivo induces LRRK2 protein destabilization in brain, lung and 
kidney. C57BL/6J mice received four intraperitoneal injections with 10 mg/kg MLi-2 or DMSO over 30 h. 
Brain, lung and kidney extracts were taken 2 h after the last injection and analyzed with immunoblotting using 
MJFF-2 anti-LRRK2 antibody, anti-LRRK2 P-S935 and anti-vinculin or α -tubulin for equal loading. Shown are 
representative blots with each lane representing a separate animal. Quantification of the blots is represented as a 
histogram and shows the ratio of total LRRK2 over vinculin or α -tubulin signal, error bars indicate s.e.m. with 
N ≥ 3, statistical significance was assessed using column statistics. **p < 0.01; *p < 0.05.
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Dundee). Antibodies used are as follows: anti-flagM2, anti-vinculin and anti-α or β -tubulin (Sigma-Aldrich), 
anti-LRRK2 MJFF-2, anti-LRRK2 P-S935, anti-LC3 (Novus Biologicals) and anti-GAPDH (Abcam). QPCR 
probes were from Sigma-Aldrich, QPCR primers from IDT. Lentiviral vectors encoding full length LRRK2 
were produced by the Leuven viral vector core (https://gbiomed.kuleuven.be/english/research/50000715/
laboratory-of-molecular- virology-and-gene-therapy/lvvc).
QPCR. LRRK2 mRNA levels were determined using RT-QPCR. Total RNA was reverse transcribed using the 
High-Capacity cDNA Archive kit (Applied Biosystems). Samples corresponding to 5 μ g RNA were subsequently 
used for QPCR analysis with the iQ5 Multicolor RT-PCR detection system (BioRad). LRRK2 primer/probe set: 
LRRK2 Fw: 5′ -ACGCAGCGAGCATTGTACCTT-3′ , LRRK2 Rev: 5′ - GGCTTCATGGCATCAACTTCA-3′ , 
LRRK2 probe: 5′ -GCTGTCTATGACCTCAGCAAGGGAC AGG C-3′ . LRRK2 mRNA levels were normalized 
to β -actin mRNA levels.
Cell lines. SH-SY5Y cells stably overexpressing 3flag-LRRK2 (WT or mutants) were generated as described in ref. 30. 
Cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-life technologies) supplemented with 
15% fetal calf serum (Gibco), 1x non-essential amino acids (Gibco), 200 μ g/ml hygromycin and 50 μ g/ml 
gentamycin at 37 °C in a humidified atmosphere containing 5% CO2. All cultures were mycoplasma-free. For 
compound treatment, cells were treated in a 24-well cell culture vessel for the indicated period of time with the 
compound indicated or DMSO as negative control. Compound concentrations were selected based on the respec-
tive cellular IC50 values1. To obtain proteasomal or lysosomal inhibition, cells were treated with 1 μ M MG132 for 
17 h or 10 μ M chloroquine for 48 h respectively, DMSO was used as negative control.
For cell lysis, cells were rinsed in PBS and lysed in lysis buffer (Tris 20 mM pH 7.5, NaCl 150 mM, EDTA 1 mM, 
Triton 1%, glycerol 10%, protease inhibitor cocktail (Roche) and phosphatase inhibitor (PhosStop, Roche)). Cell 
lysates were cleared by centrifugation at 14,000 g for 10 min and further analyzed via immunoblot.
Figure 4. LRRK2 kinase inhibition in primary astrocytes. (a) Primary astrocytes were treated with GSK2578215A 
(GSK, 2 μ M), CZC-25146 (CZC, 200 nM), HG 10-102-01 (HG, 1 μ M) or PF-06447475 (PF, 150 nM) for 90 min or 
48 h or with a tenfold dilution of the concentrations mentioned for 5 or 10 days with fresh compound every two days. 
Immunoblotting was done with MJFF-2 anti-LRRK2 antibody, anti-LRRK2 P-S935 and anti-β -tubulin for equal 
loading. Representative blots are shown. (b) Quantifications of the blots represent total LRRK2 signal over β -tubulin. 
Statistical significance was assessed by column statistics (one-sample t-test) with Bonferroni correction for multiple 
comparisons. *p < 0.05.
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Primary cortical astrocyte cultures. Mixed cortical cell isolation for astrocyte cultures were performed 
using P1 to P4 mouse pups. Isolated cortex was mechanically dissociated and cells were cultured in BME sup-
plemented with 10% FBS. After 10 days in culture, astrocyte purity was examined by immunofluorescence with 
anti-GFAP antibody (Dako).
Brain extracts. All animal experiments were performed in accordance with the European Communities 
Council Directive of November 24, 1986 (86/609/EEC) and approved by the Bioethical Committee 
of the KU Leuven (Belgium). C57BL/6J mice were injected i.p. with 10 mg/kg MLi-2 or DMSO in 
hydroxypropyl-β -cyclodextrin (Sigma-Aldrich) and PBS. Four injections were given in total over 30 h and ani-
mals were sacrificed 2 h after the last injection. Whole brain, lung and kidney extracts were lysed in sucrose buffer 
(10 mM TrisHCl, 1 mM EDTA, 0.25 mM sucrose, protease inhibitor cocktail and phosphatase inhibitor) using a 
dounce homogenizer. Brain extracts were cleared by 10 min centrifugation at 3000 g followed by centrifugation of 
the supernatant for 30 min at 20000 g.
Immunoblotting. Protein content of cell lysates was determined using the bicinchoninic acid (BCA) protein 
determination assay (Pierce Biotechnology). Cell lysates were resolved by electrophoresis on an in-house 12.5% 
polyacrylamide gel or a NuPage 3–8% tris-acetate gradient gel. Separated proteins were transferred to a polyvi-
nylidene fluoride membrane (Bio-Rad) and non-specific binding sites were blocked for 30 min in PBS with 0.1% 
Triton X-100 (PBST) and 5% non-fat milk. After overnight incubation at 4 °C with primary antibo-dies, blots 
were washed 3 times with PBST, incubated with horseradish peroxidase-conjugated secondary antibody (Dako, 
Glostrup) for 1 h and washed again. Bands were visualized using enhanced chemiluminescence (Amersham 
Pharmacia Biotech). To normalize the signal of phospho-specific antibodies to LRRK2 expression levels, blots 
were stripped after detection of the LRRK2 signal and reprobed with anti-phospho-LRRK2 antibody by incubat-
ing the blot with stripping buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS and 100 mM β -mercaptoethanol) for 30 min 
at 70 °C, followed by 2 10 min wash steps with PBST. Densitometric analysis of the bands on the blot autoradio-
grams was performed with Aida analyzer v1.0 (Raytest).
Statistics. Figures shown are representative of at least three independent experiments. Phosphorylation levels 
were normalized for expression levels and experimental test conditions for control conditions. Statistical analysis 
was performed with a t-test, two-way ANOVA test or column statistics (one-sample t-test) comparing test values 
to the hypothetical value of 1 with Bonferroni correction for multiple comparisons. Statistical significance was 
set at p < 0.05.
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